AccessMyLibrary provides FREE access to millions of articles from top publications available through your library.
Close
Create a link to this page
Copy and paste this link tag into your Web page or blog:
<a href="http://www.accessmylibrary.com/article-1G1-252715921/h-lundbeck-2010-markets.html" title="Facts and information about H Lundbeck 2010: Markets for Huntington's disease treatments, Epilepsy treatments, and Bipolar disorder treatments.">H Lundbeck 2010: Markets for Huntington's disease treatments, Epilepsy treatments, and Bipolar disorder treatments.</a>
Close
Set up an RSS feed that alerts you when new articles from Chemical Business Newsbase are available.
Frequently asked questions about RSS feeds
H Lundbeck 2010: Markets for Huntington's disease treatments, Epilepsy treatments, and Bipolar disorder treatments.
For its fiscal 2010, H Lundbeck A/S has reported sales of Xenazine (Huntington's) of DKR 610 M (DKR 298 M for fiscal 2009) and Sabril (epilepsy) DKR 179 M (no …
Related articles from newspapers, magazines, journals, and more
-
- Lundbeck ready to launch Sycrest in 15 European countries.
-
News wire article from: Chemical Business Newsbase
April 4, 2011
700+ words
